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Coendemicity between the human immunodeficiency virus (HIV) and Plasmodium
parasites, the causative agents of acquired immunodeficiency syndrome (AIDS) and
malaria, respectively, occurs in several regions around the world. Although the impact
of the interaction between these two organisms is not well understood, it is thought
that the outcome of either disease may be negatively influenced by coinfection.
Therefore, it is important to understand how current first-line antiretroviral therapies
(ART) might impact Plasmodium infection in these regions. Here, we describe the effect
of 18 antiretroviral compounds and of first-line ART on the blood and sporogonic
stages of Plasmodium berghei in vitro and in vivo. We show that the combination
zidovudine + lamivudine + lopinavir/ritonavir (LPV/r), employed as first-line HIV
treatment in the field, has a strong inhibitory activity on the sporogonic stages of
P. berghei and that several non-nucleoside reverse transcriptase inhibitors (NNRTI) have
a moderate effect on this stage of the parasite’s life cycle. Our results expose the effect of
current first-line ART on Plasmodium infection and identify potential alternative therapies
for HIV/AIDS that might impact malaria transmission.
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INTRODUCTION
In 2018, an estimated 228 million people suffered from malaria, killing 405,000 (World Health
Organization [WHO], 2019a). Malaria is caused by Plasmodium parasites that are transmitted
to their mammalian host by the bite of female-infected Anopheles mosquitoes (Prudêncio et al.,
2011). Sporozoites injected into the skin during a blood meal eventually reach the bloodstream
and migrate to the liver, initiating the hepatic stage of the infection (Mota et al., 2001). Merozoites
formed during parasite replication inside hepatocytes are released into the bloodstream, giving rise
to the clinical symptoms of the disease (Prudêncio et al., 2011). When a mosquito takes a blood
meal from an infected mammalian host, it ingests Plasmodium gametocytes that will subsequently
differentiate into female and male gametes and fuse to form a zygote (Sinden et al., 2010). After
18–24 h, the zygote transforms into an ookinete, traverses the midgut epithelium, and settles in the
basal lamina of the midgut wall, rounding up into an oocyst (Vinetz, 2005). During the ensuing
10–13 days, oocysts increase in size, producing thousands of sporozoites that will be released
in the hemolymph and travel to the mosquito salivary glands, completing the cycle (Baton and
Ranford-Cartwright, 2005; Staines and Sanjeev, 2012).
Human immunodeficiency virus (HIV) infects the immune system’s CD4+ T cells, inducing
chronic inflammation that drives the progression into acquired immune deficiency syndrome
(AIDS) (HIV/AIDS, 2019: The Basics Understanding HIV/AIDS). In 2018, 37.9 million people
were reported to live with HIV, leading to an estimated 770,000 deaths in that year alone
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(World Health Organization [WHO], 2019b). In 2002, the
World Health Organization (WHO) issued a set of guidelines
to help determine the best usage of antiretroviral (ARV)
compounds for the treatment of HIV-positive young adults and
adolescents (World Health Organization [WHO], 2016). Since
then, these guidelines have been regularly updated, and, since
2016, the recommended first-line antiretroviral therapies (ART)
in adults, including pregnant women and adolescents, consist
of two nucleoside reverse-transcriptase inhibitors (NRTIs) plus
a non-nucleoside reverse transcriptase inhibitors (NNRTI) or
an integrase strand transfer inhibitor (INSTI) (World Health
Organization [WHO], 2016). The recommendation for children
between 3 and 10 years old is the combination of two NRTIs
with the NNRTI efavirenz (EFV), while for children under 3 years
of age, a combination of the NRTI backbone with the protease
inhibitors (PIs) lopinavir/ritonavir (LPV/r) is recommended
(World Health Organization [WHO], 2016).
Plasmodium and HIV infections overlap geographically in
tropical and subtropical regions, particularly in Sub-Saharan
Africa, where 70% of the world’s HIV cases and 93% of the
malaria cases are concentrated (Kwenti, 2018; World Health
Organization [WHO], 2019a). Pregnant women, in whom
Plasmodium infections are more severe, are at particular risk
of coinfection (Kharsany and Karim, 2016; Kwenti, 2018). The
outlook of either disease seems to be influenced by coinfection.
On the one hand, the low CD4+ cell count of HIV carriers
limits their immune system’s ability to mount a response against
a parasite infection (Skinner-Adams et al., 2008), while on the
other hand, Plasmodium infection can cause T-cell activation
and cytokine release, which can stimulate HIV replication
(Xiao et al., 1998; Skinner-Adams et al., 2008). Therefore, it
is important to further understand the spectrum of activity of
drugs used for treatment of either disease and their possible
impact on each other.
Numerous reports describe the effect of ART on the blood
and liver stages of Plasmodium parasites (Butcher, 1997; Skinner-
Adams et al., 2004; Parikh et al., 2005; Hobbs et al., 2009,
2012; Peatey et al., 2010, 2012; Nsanzabana and Rosenthal, 2011;
Machado et al., 2017). PIs have been systematically described as
the most effective ARVs in inhibiting Plasmodium erythrocytic
stages (Skinner-Adams et al., 2004; Parikh et al., 2005; Andrews
et al., 2006; Lek-Uthai et al., 2008; Peatey et al., 2010; Nsanzabana
and Rosenthal, 2011; Hobbs et al., 2013). Their ability to inhibit
the growth of drug-susceptible and drug-resistant Plasmodium
falciparum parasite strains has also been documented (Skinner-
Adams et al., 2004; Nsanzabana and Rosenthal, 2011). The PI
lopinavir (LPV) has been identified by several studies as the
most potent ARV inhibiting P. falciparum asexual stages in vitro
(Parikh et al., 2005; Nsanzabana and Rosenthal, 2011; Hobbs
et al., 2013). The PI indinavir (IDV) has also been reported to
suppress Plasmodium cynomolgi growth and to delay prepatency
in monkeys infected with Plasmodium knowlesi (Li et al., 2011).
Plasmodium vivax was found to be more sensitive to the PIs
ritonavir (RTV) and saquinavir (SQV) than P. falciparum (Lek-
Uthai et al., 2008), whereas Peatey et al. (2010) showed that
ARV PIs are more active against the trophozoite and schizont
stages than against the ring stages of P. falciparum asexual
parasites in the blood. These authors also showed that the
exposure of P. falciparum gametocyte cultures to SQV, LPV, RTV,
tipranavir, and darunavir (DRV) (PIs) inhibited the formation
of gametocytes–gametocytogenesis, but only tipranavir had the
ability to kill gametocytes (Peatey et al., 2010). Consistent with
these results, Hobbs et al. (2013) showed that prolonged drug
exposure to LPV/r, LPV, and SQV reduces early- and late-stage
gametocyte viability, with the latter two drugs impacting parasite
exflagellation. This impairment in parasite development was also
reflected on oocyst infection in the mosquito, when mosquitoes
were allowed to feed on blood cultures previously treated with
LPV and SQV (Hobbs et al., 2013).
The mechanism of action of PIs on Plasmodium is still
unknown, but it has been theorized that PIs inhibit the
development of malaria parasites by targeting plasmepsins (PMs)
in their food vacuole (Savarino et al., 2005; Andrews et al., 2006),
where they play an important role in hemoglobin degradation
by P. falciparum (Liu et al., 2005). More recently, it has been
suggested that the these drugs might also target other non-
vacuolar PMs (Skinner-Adams et al., 2007; Peatey et al., 2010; Li
et al., 2011; Onchieku et al., 2018). Another study suggested that
treatment with PIs might affect positively the outcome of malaria
infection due to an impairment of parasite sequestration by these
drugs. This impairment could be explained by the deficiency in
the CD36 receptor observed in some patients treated with ARVs
(Nathoo et al., 2003). A recent investigation of the impact of
ARVs on the liver stage of Plasmodium infection has shown that,
consistent with what is observed for erythrocytic stages, the PIs
LPV and RTV are potent inhibitors of the parasite’s development
in hepatic cells (Hobbs et al., 2009). A reduction in the in vivo
Plasmodium yoelii liver burden by NNRTIs (Hobbs et al., 2012)
and of the in vivo Plasmodium berghei liver burden by etravirine
(ETV) (Machado et al., 2017) have also been reported.
In this study, we employed a recently developed
luminescence-based in vitro assay (Azevedo et al., 2017) to
determine the ability of ARVs and current first-line ARTs to
inhibit the development of Plasmodium mosquito stages in vitro.
We further validated those results by assessing the in vivo
inhibitory activity of the first-line ARTs and selected alternative
drug combinations against the sexual stages of the parasite’s life
cycle, as well as their impact on oocyst infection. This study
demonstrates that the current field treatments against HIV have
an impact on the mosquito stages of Plasmodium and suggest the
evaluation of the possible inclusion of both rilpivirine (RPV) and
ETV in alternative ARTs.
MATERIALS AND METHODS
Animals and Parasite Lines
Six- to eight-week-old male BALB/cByJ mice were purchased
from Charles River Laboratories Inc. (France). The PbCSGFP-
Luc (Azevedo et al., 2017) and PbFluo-frmg (Ponzi et al., 2009)
P. berghei parasite lines were employed in the experimental work,
all of which was carried out under BSL1 or ABSL2 conditions.
The former parasite line expresses the fusion gene gfp-luc under
the control of the csp gene promotor (RMgm-152), and the latter
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expresses red fluorescent protein and green fluorescent protein
(GFP) under the control of stage-specific promotors for female
and male gametocytes, respectively (RMgm-164). The genes were
integrated by double recombination into the silent 230p gene
locus of the P. berghei genome.
Ookinete Production and Culturing
Ookinetes were generated as previously described (Azevedo
et al., 2017). Briefly, two male BALB/cBbyJ mice were infected
with 107 PbCSGFP-Luc-infected red blood cells (RBCs) 3 days
posttreatment with 0.1 ml phenylhydrazine (25 mg/ml). On
the third day of infection, when three to six exflagellation
events/field (1:4 dilution) were observed by light microscopy
field (40 × magnification), mice were killed, and ∼2 ml of
infected blood was collected by cardiac puncture and added to
Roswell Park Memorial Institute (RPMI) 1640 Medium (Sigma)
37◦C. After washing with RPMI, 5 µl of blood and 195 µl of
ookinete culturing medium [RPMI-1640, 25 mM HEPES, 0.4 mM
hypoxanthine, 100 mM xanthurenic acid (Fluka, 85570), 10%
fetal bovine serum, pH 7.6] were added per well of a 96-well
plate and incubated for 24 h at 19◦C for ookinete formation.
In parallel, a 1:20 dilution of blood in ookinete medium was
cultured in T75 flasks for 22–24 h at 19◦C for the production of
ookinetes. Ookinetes were purified employing a Nycodenz (Axis-
Shield) gradient. The contents of the T75 flask were collected,
and the RBCs were lysed for 15 min on ice with 30 volumes of
ice-cold 0.17 M ammonium chloride. After removal of the lysed
RBCs by washing with RPMI-1640, ookinetes were purified on
a 69% Nycodenz gradient by centrifugation at 650 × g and 4◦C
for 30 min. Following centrifugation, ookinetes were collected by
aspiration of the dark brown ring formed, washed in RPMI-1640,
and resuspended in 1 ml of oocyst medium [Schneider’s medium
(Sigma S0146), 15% fetal bovine serum, penicillin/streptomycin
(50 U/ml, 50 µg/ml), and gentamicin (50 µg/ml)].
Oocyst Cultures
Following purification, ookinetes were cocultured with
Drosophila melanogaster S2 cells (Drosophila Genomics Resource
Center, Bloomington, IN, United States) in a 1:10 ratio (104
ookinetes and 105 S2 cells) in oocyst medium, as previously
described (Azevedo et al., 2017). The cultures were maintained
in 96-well plates for up to 15 days at 19◦C. One quarter of the
medium volume was replaced by fresh medium three times a
week, and 105 S2 cells were added to the medium once per week.
Evaluation of the Activity of ARV
Compounds Against Plasmodium
Mosquito Stages in vitro
The activity of 10 µM of each ARV compound was independently
assessed against ookinetes and oocysts. This concentration
was selected based on the standards established by previous
experimental work by Delves et al. (2012) and Azevedo et al.
(2017) on the Plasmodium transmission blocking effect of
various compounds and after a preliminary screen of all the
compounds under evaluation at 50, 10, and 1 µM. Eighteen
compounds belonging to four different classes of ARVs were
evaluated: (1) PI – amprenavir (APV), atazanavir (ATV), DRV,
IDV, LPV, nelfinavir (NFV), RTV, and SQV; (2) INSTIs –
raltegravir (RAL); (3) NRTIs – abacavir (ABC), tenofovir (TDF),
emtricitabine (FTC), zidovudine (AZT), and lamivudine (3TC);
and (4) NNRTIs – ETV, nevirapine (NVP), EFV, and RPV.
Drug combinations in vitro assays contained 10 µM of each
compound. ARV compounds were obtained from the NIH
AIDS and Reference Reagent Program. Ten millimolars stock
solutions of the compounds was prepared in dimethyl sulfoxide
(DMSO), and serially diluted compounds were employed for
activity assessments. A concentration of DMSO equivalent to
that present in the highest compound concentration was also
used as a control in all activity assays. The compounds’ effect
on gametocyte to ookinete transition was determined by adding
them to 1-h-old gametocyte cultures. After 24 h, the parasite load
was assessed by bioluminescence employing the Firefly Luciferase
Assay Kit (Biotium) according to the manufacturer’s instructions,
with some modifications. Briefly, the well contents were collected,
washed with PBS, spun down, and frozen in 50 µl of 1:5 lysis
buffer. Thirty microliters of the lysed supernatant was transferred
into each well of a white 96-well plate. Fifty microliters of luciferin
Firefly Luciferase Assay buffer (1:50 ratio) was added to the
samples, and the parasite load was determined by measuring
luminescence intensity using a microplate reader (Tecan Infinite
M200). To assess their effect on oocyst formation, compounds
were mixed with ookinetes and cultured with D. melanogaster
S2 cells for 3 days, following which the cultures were collected
and lysed, and parasite load was determined by luminescence
measurement, as described above. The effect of the compounds
on oocyst development was assessed by adding them to 3-day-old
oocyst cultures, lysing the cultures 12 days later, and determining
the parasite load by bioluminescence, as described above.
Evaluation of the Activity of ARV
Compounds Against Plasmodium Blood
and Mosquito Stages in vivo
To evaluate the in vivo antiplasmodial activity of first-line ARV
regimens and proposed modifications, three male BALB/cByJ
mice per experimental group were infected with 107 infected
RBCs of the parasite line PbFluo-frmg from a donor previously
infected from a parasite stock vial. After 24 h, and during the
following 4 days, parasitemia and gametocytemia were assessed
by the collection of 4 µl of tail blood in 200 µl of PBS. One
hundred microliters of the solution was further diluted in PBS at
a 1:1 ratio and stored at 4◦C, while the remainder was diluted in
a 1:1 ratio of PBS containing 1.25 mM of red fluorescent nucleic
acid stain Syto R© 61 (ThermoFisher Scientific) and incubated for
20 min at room temperature in the dark. The samples were
analyzed on an LSR Fortessa X-20 flow cytometer (Becton,
Dickinson and Company). Forty-eight hours postinfection, a
suspension of the compounds in sunflower oil was administered
by oral gavage. Compounds were administered at an allometry-
scaled dose, and in accordance with the administration regimen
recommended for humans, all the compounds were administered
on a 24-h schedule except for ETV, which was administered every
12 h (Supplementary Table S1). DMSO in a dosage equivalent to
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that present in the highest compound combination was used as
a control. On the fifth day of infection, ∼50 previously starved
Anopheles stephensi mosquitoes per experimental condition
were allowed to feed for ∼30 min on anesthetized, infected,
drug-treated mice. Mosquitoes were kept in standard dietary
conditions, at 20◦C with 80% humidity under a 12-h light/dark
cycle. Ten days after infection, mosquito midguts were dissected
and stained with a solution of 0.025% mercurochrome to
quantify oocyst infection by microscopy analysis. Images were
acquired on a Leica DM2500 and analyzed with the FIJI software
(Schindelin et al., 2012).
Statistical Analysis
Data regarding the compounds’ in vitro effect and mosquito
infection were analyzed using the Kruskal–Wallis test.
A chi-squared test was used to compare mosquito infection
prevalence. Data on the compounds’ effect on parasitemia
and gametocytemia in vivo were analyzed by non-linear
regression analysis. Results were considered significant for
P < 0.05. All statistical tests were performed using the GraphPad
Prism software (version 6.00, GraphPad Software, La Jolla,
CA, United States).
Ethics Statement
All work with laboratory animals was performed
according to National and European regulations (Directive
2010/63/EU). All protocols were approved by the Animal
Experimentation Ethics Committee (AWB_2015_09_MP_
Malaria) of the Instituto de Medicina Molecular João Lobo
Antunes and are in accordance with the Federation of European
Laboratory Animal Science Associations (FELASA) guidelines.
RESULTS
In vitro Activity of ARV Compounds
Against Ookinete Formation
The activity of a 10-µM concentration of each of 18 ARV
compounds from 4 different drug classes – PI: APV, ATV,
DRV, IDV, LPV, NFV, RTV, and SQV; INSTIs: RAL; NRTIs:
ABC, FTC, 3TC, TDF, and AZT; and NNRTIs: EFV, ETV, NVP,
and RPV – against P. berghei sporogonic stages in vitro was
evaluated (Figure 1A). Our results showed that the PIs LPV
and RTV led to at least 60% reduction in ookinete formation
relative to the controls, whereas the NNRTI ETV inhibited
parasite development by ∼40% (Figure 1B and Supplementary
Table S2). Conversely, neither of the NRTI and INSTI
compounds under evaluation displayed an inhibitory activity
against this stage of the parasite’s sporogonic development at the
concentration used in this assay (Figure 1B).
In vitro Effect of ARVs on Oocyst
Formation and Development
We subsequently assessed the activity of the 18 compounds
listed above on oocyst formation and development. Our
results showed that 10 µM concentrations of the NNRTIs
FIGURE 1 | In vitro activity of ARV compounds on P. berghei sporogonic
stages. (A) Timeline of P. berghei sporogonic development and drug
incubation periods. (B) Activity of ARV compounds on the conversion of
zygotes/gametes into ookinetes. (C) Activity of ARV compounds on oocyst
formation. (D) Activity of ARV compounds on oocyst development. All
compounds were employed at 10 µM. Bars correspond to RLU
measurements represented as the percentage of RLU of the DMSO control.
Results are expressed as the mean ± SD. Statistically significant differences
between control and treated conditions were analyzed using the
Kruskal–Wallis test. N = 3–6. ***P < 0.001; **P < 0.01; *P < 0.05. Detailed
statistical analysis is presented in Supplementary Table S2.
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RPV and ETV inhibited oocyst formation by ∼60 and 50%,
respectively. A milder effect has observed for two PIs, with
RTV inhibiting oocyst formation by ∼40% and LPV by ∼35%
(Figure 1C and Supplementary Table S2). The PIs IDV,
SQV, and RTV, as well as the NNRTI RPV, led to more
than 50% inhibition of oocyst development (Figure 1D and
Supplementary Table S2). Smaller effects were observed for the
NNRTIs EFV and ETV, which impaired oocyst development by
∼45 and ∼30%, respectively (Figure 1D and Supplementary
Table S2). Interestingly, treatment with the NRTIs ABC and
3TC consistently led to increased parasite loads relative to
vehicle-treated controls (Figure 1D). None of the remaining
compounds under evaluation displayed activity against either
oocyst formation or development.
In vitro Activity of First-Line Regimen
ART Against P. berghei Sporogonic
Stages
According to WHO recommendations, ARV should be
administered as an integral part of well-established ART
regimens. The preferred backbone for first-line treatment against
HIV in adults and adolescents is composed of two NRTIs and
an NNRTI or INSTI, while for treatment of children <3 years
old, WHO’s suggested drug combination is AZT+ 3TC+ LPV/r
(World Health Organization [WHO], 2016). We assessed
the activity of the first-line ARV regimen for adults and
adolescents, TDF (NRTI) + 3TC (NRTI) + EFV (NNRTI),
and children, AZT (NNRTI) + 3TC (NNRTI) + LPV/r (PIs),
against the parasite’s sporogonic development (Figures 2A–C).
In parallel, informed by our results regarding the activity of
individual ARV compounds, we evaluated alternative drug
combinations for adults and adolescents where EFV was replaced
by either of the NNRTIs ETV or RPV, and alternative drug
combinations for children where LPV/r was replaced by either
of the best performing PIs in the individual screen, SQV or
IDV (Figures 2A–C). Our results showed that a combination
of 10 µM of the drugs AZT + 3TC + LPV/r displayed a
∼50% inhibitory activity against gametocyte to ookinete
transition, whereas the drug combinations TDF + 3TC + ETV
and RPV inhibited this process by ∼30% (Figure 2A). The
combinations AZT + 3TC + LPV/r and TDF + 3TC + RPV
markedly inhibited oocyst formation (∼90 and 80% inhibition,
respectively), and development (∼50 and ∼40% inhibition,
respectively), whereas TDF + 3TC + ETV inhibited oocyst
formation by 70% but had no effect on oocyst development.
Finally, the combination of TDF+ 3TC+ EFV also resulted in a
∼50% reduction of oocyst development but showed no effect on
oocyst formation (Figures 2B,C).
Evaluation of ART Effect on P. berghei
Sporogonic Stages in vivo
To validate our in vitro results, the antiplasmodial effect of
the first-line drug combinations TDF + 3TC + EFV and
AZT + 3TC + LPV/r, were evaluated in an in vivo setting
(Figure 3A). Informed by our in vitro data, ETV and RPV were
also screened in combination with TDF + 3TC. Our results
showed that neither of the drug treatments employed had an
impact on P. berghei parasitemia and gametocytemia, when
compared with vehicle-treated mice (Figures 3B–D). Our data
further showed that the drug combination AZT + 3TC + LPV/r
displayed a strong ∼90% impact on median oocyst infection in
the mosquitoes, whereas the remaining drug combinations with
EFV, ETV, and RPV led to smaller reductions in the intensity
of infection (Figure 3E and Supplementary Table S2). This
reduction does not result from an increase in the number of
non-infected mosquitoes, but rather from a reduction in the
oocyst load on infected mosquitoes, which is also significant
upon treatment with the TDF + 3TC + EFV combination
(Figures 3F,G and Supplementary Table S3).
DISCUSSION
Human immunodeficiency virus and Plasmodium coinfections
raise serious concerns in the regions where both organisms
overlap geographically (Kharsany and Karim, 2016; Kwenti,
2018). It has been hypothesized that the interaction between
HIV and Plasmodium is both synergistic and bidirectional. Thus,
infection with HIV might increase the severity of Plasmodium
infection, while the HIV viral load has been shown to increase
during a Plasmodium infection (Nyabadza et al., 2015; Kwenti,
2018). Numerous studies report the effect of HIV ARVs on the
different stages of the Plasmodium life cycle (Parikh et al., 2005;
Andrews et al., 2006; Lek-Uthai et al., 2008; Hobbs et al., 2009,
2012, 2013; Peatey et al., 2010; Li et al., 2011; Nsanzabana and
Rosenthal, 2011; Machado et al., 2017). However, little is known
about how ARTs may impair the transmission and mosquito
stages of Plasmodium parasites.
The results presented here show that the several ARV
compounds impair various stages of Plasmodium sporogonic
development in vitro and that the WHO-recommended first-
line ARTs employed against HIV have a significant impact on
Plasmodium infection in the mosquito vector (Figures 3E,G).
However, neither of the current first-line ART nor the
alternative combinations evaluated in this work inhibited
P. berghei asexual and gametocyte stages at clinically relevant
concentrations in vivo (Figures 3B–D). It has been shown
that HIV infection leads to an increase in the production of
proinflammatory cytokines tumor necrosis factor, interleuking
(IL)-1β, and IL-6, which can be partially reversed by ART
(Amirayan-Chevillard et al., 2000; Kedzierska and Crowe, 2001),
suggesting a possible indirect effect of ART on Plasmodium
infection. However, the lack of impact of ARVs on the
blood stages of Plasmodium in vivo suggests that a different
mechanism may be responsible for the effects observed
on the parasite’s sporogony. Our results suggest that PIs
might either affect the parasite’s fusing process by impairing
exflagellation in vitro, as previously suggested for P. falciparum
(Hobbs et al., 2013), or act further downstream of the
fertilization process.
Similarly to what has previously been shown for the blood
stages of P. falciparum (Parikh et al., 2005; Andrews et al.,
2006; Peatey et al., 2010; Nsanzabana and Rosenthal, 2011;
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FIGURE 2 | In vitro activity of ART on the P. berghei sporogonic stages. (A) Effect of first-line ART employed for adults and adolescents and for children under
3 years old and suggested substitutions on the conversion of zygotes/gametes into ookinetes. (B) Activity of first-line ART and suggested substitutions on oocyst
formation. (C) Activity of first-line ART and suggested substitutions on oocyst development. All compounds were screened at 10 µM; TDF, tenofovir; 3TC,
lamivudine; EFV, efavirenz; ETV, etravirine; RPV, rilpivirine; AZT, zidovudine; LPV/r, lopinavir/ritonavir; SQV, saquinavir; IDV, indinavir. RLU measurements represented
as the percentage of RLU of the DMSO control. Statistically significant differences between control and treated conditions were analyzed using the Kruskal–Wallis
test. Results are expressed as the mean ± SD. N = 3–4. ***P < 0.001; **P < 0.01; *P < 0.05.
Hobbs et al., 2013), our results indicate that PIs display the
strongest in vitro inhibitory activity against P. berghei transition
from gametocytes to ookinetes (Figure 1B). It has been suggested
that PIs act on PMs, a class of Plasmodium’ aspartic proteases
(Parikh et al., 2005; Bonilla et al., 2007; Skinner-Adams et al.,
2007; Peatey et al., 2010). Although HIV aspartic proteases
are structurally different from Plasmodium PMs, several of the
latter have been described in the sexual stages of P. falciparum,
P. berghei, and P. yoelii (Hall et al., 2005; Young et al., 2005).
Our results show that PIs strongly inhibit the formation and
development of oocysts in vitro (Figures 1C,D). Accordingly,
the first-line ART containing the PIs LPV/r had the strongest
impact on oocyst intensity in vivo (Figures 3E,G). Although,
to the best of our knowledge, the effect of ARVs on ookinetes
has not been previously reported, it is known that PMs IV, VII,
and X (Li et al., 2010, 2016) are expressed by this parasite stage,
thus providing a possible explanation for the effect of PIs on
the transformation of ookinetes into oocysts. Moreover, PM VI,
whose role is yet undefined, seems crucial for the early oocyst
stages of sporogonic development (Li et al., 2016). Thus, the
observed inhibition of oocyst formation and development in vitro
by PIs (Figures 1C,D) may suggest that PM VI could be the target
of drugs belonging to this class.
We further observed that LPV and RTV had a stronger
inhibitory activity on sporogony when tested in combination
than individually (Figures 1B–D and 2A–C). RTV is currently
administered exclusively as a pharmacokinetic enhancer of other
PIs due to its effect on cytochrome P450 3A4 isoenzyme (Hull
and Montaner, 2011). However, since this enzyme is absent
from the in vitro system employed here, the results obtained
may be explained by an additive effect of LPV and RTV. We
also observed a moderate inhibition of the sporogonic stages
of P. berghei in vitro by several NNRTIs (Figures 1A–C).
A reverse transcriptase telomerase has been previously identified
and characterized in P. falciparum (Figueiredo et al., 2005), and
although it differs from HIV’s reverse transcriptase, it might
contribute to explaining the observed effect of these drugs
on the early and late oocyst stage of the parasite’s life cycle
(Figures 1C,D).
Both the first-line ART and the alternative ARV combinations
tested here had similar impacts on oocyst infection in
the mosquito (Figures 3E,G). Our results show that the
current first-line ART for children under 3 years old
AZT + 3TC + LPV/r is the drug combination that most
effectively inhibits the sporogonic stages of P. berghei
in vivo. Interestingly, previous studies showed that LPV/r
inhibits oocyst infection in P. falciparum (Hobbs et al., 2013)
and reduces parasite P. yoelii liver burden (Hobbs et al.,
2009). The impact of current first-line ART for adults and
adolescents on mosquito infection, which includes EFV,
was similar to that of the suggested alternatives employing
ETV and RPV. A previous study by Machado et al. (2017)
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FIGURE 3 | In vivo activity of ART on blood and transmission stages of P. berghei. (A) Schematics of drug administration and sample collection schedules. (B–D)
Activity of ART and suggested alternative drug combinations on P. berghei parasitemia (B), female (C), and male (D) gametocytemia in mice. Results are expressed
as the mean percentage of syto 61-positive events ± SD for parasitemia, percentage of RFP+ events for female gametocytemia and percentage of GFP+ for male
gametocytemia. (E) Impact of ART and suggested alternatives on P. berghei mosquito infection measured as oocyst intensity per mosquito. Results are represented
individually by number of parasites per mosquito midgut. Horizontal red and black lines represent median and mean, respectively. (F) Prevalence of oocyst infection
in mosquitoes infected with P. berghei expressed as the mean ± SD. (G) Average P. berghei oocyst infection intensity upon ART and suggested alternatives in
infected mosquitoes. Box plot represent the median and 25th and 75th percentile. N = 2. ***P < 0.001; **P < 0.01. In (B–D), statistically significant differences
between control and treated conditions for blood stage P. berghei development were analyzed using a non-linear regression analysis. In (E), Kruskal–Wallis test was
used to calculate P values and determine the significance of parasite numbers. A chi-squared test was used to compare infection prevalence values in (F). Detailed
statistical analysis is presented in Supplementary Table S3.
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identified ETV as a stronger inhibitor of the hepatic stages of
P. berghei than the current recommended ART with EFV.
Overall, our results suggest that both ETV and RPV, as
well as other ARVs that may have an impact on Plasmodium
transmission, should be contemplated when considering
alternative ARTs in malaria-endemic regions. However, to
fully ascertain the possible impact of these findings in such
settings, additional work is required to assess the impact of
these compounds on transmission of P. falciparum sporozoites.
Furthermore, given the importance of the mosquito microbiota
on infection by Plasmodium, it would be interesting to replicate
our results obtained in vivo in mosquitoes depleted of microbiota
(Dong et al., 2009; Kalappa et al., 2018). Finally, a further
understanding of the mechanism of action of ARVs against
Plasmodium parasites is essential for developing new drugs
that might have both ARV and antiplasmodial activity. By
identifying the target of HIV PIs on Plasmodium parasites,
new drugs could be developed that have a stronger impact on
Plasmodium infection.
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